> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-126/
- Published: 2017-03-12T12:00:00.000Z
- Updated: 2026-09-14T22:11:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138182

[**Drug Safety/Anesthetic and Analgesic Meeting Address Change**](https://www.fdaweb.com/drug-safety-anesthetic-and-analgesic-meeting-address-change/)  
*Federal Register* Notice: FDA amends a 1/11 notice of a Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee joint meeting. 03/08/2017 

[**Flonase Not Withdrawn Due to Safety/Effectiveness**](https://www.fdaweb.com/flonase-not-withdrawn-due-to-safety-effectiveness/)  
*Federal Register* Notice: FDA determines that GlaxoSmithKline’s allergy drug Flonase (fluticasone propionate) nasal spray, 0.05 mg, was not withdrawn from sale for safety or effectiveness reasons. 03/06/2017 

[**Public Meeting on Autism Drug Development**](https://www.fdaweb.com/public-meeting-on-autism-drug-development/)  
*Federal Register* Notice: FDA announces a 5/4 public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. 03/06/2017 

[**Biogen Awarded Priority Review Voucher**](https://www.fdaweb.com/biogen-awarded-priority-review-voucher/)  
*Federal Register* Notice: FDA awards Biogen a priority review voucher for gaining approval of rare disease drug Spinraza (nusinersen), indicated for treating spinal muscular atrophy in pediatric and adult patients. 03/06/2017